Melissa P. DelBello
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Melissa P. DelBello has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Caleb M. Adler
Division of Bipolar Disorders Research, Department of Psychiatry & Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA; Center for Imaging Research, University of Cincinnati College of Medicine, Cincinnati, OH, USA
4 shared publicationsSamantha M. Bitter
Division of Bipolar Disorders Research, Department of Psychiatry & Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA
4 shared publicationsStephen M. Strakowski
Division of Bipolar Disorders Research, Department of Psychiatry & Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA; Center for Imaging Research, University of Cincinnati College of Medicine, Cincinnati, OH, USA
4 shared publications- Caleb M. Adler
Department of Psychiatry and Behavioral Neuroscience, Division of Bipolar Disorders Research, University of Cincinnati College of Medicine, Cincinnati, OH, USA
2 shared publications Jaimee L. Heffner
Fred Hutchinson Cancer Research Center, Seattle, WA, and the Division of Bipolar Disorders Research, University of Cincinnati College of Medicine
2 shared publicationsJeffrey A. Welge
Department of Psychiatry and Behavioral Neuroscience Division of Bipolar Disorder Research University of Cincinnati College of Medicine Cincinnati OH USA
2 shared publications
Latest Publications
- 28 August 2020
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 30 (7) , 465-469
A Preliminary Study of the Effects of Treatment with Lithium Versus Quetiapine on Attention of Adolescents with Bipolar Disorder
Objectives: Despite attentional deficits being a prominent feature of bipolar disorder, there are limited data on the effects of common treatments for bipolar disorder on attention. Thus, we sought to compare the effects of lithium versus quetiapine on attention in adolescents with bipolar disorder. Methods: Adolescents ages 10–17 with bipolar disorder, type I, who were experiencing a manic or mixed episode, were recruited from outpatient settings and the inpatient psychiatric units at Cincinnati Children's Hospital Medical Center during their first manic episode. Healthy comparison subjects were recruited from outreach programs in the community. Patients were randomized to lithium or quetiapine, administered in a double-dummy, double-blinded manner for 6 weeks. Attentional deficits were assessed in all groups using the Identical Pairs Continuous Performance Task at baseline and at week 6. Results: Patients with bipolar disorder ( n = 79) had impaired attention relative to the healthy group ( n = 57) at both baseline and after 6 weeks of treatment. The lithium-treated group ( n = 30) had poorer attentional performance than the healthy group at week 6. There was a difference in change in performance between lithium- and quetiapine-treated ( n = 49) groups. Conclusion: Youth with bipolar disorder may have impaired attention relative to their healthy peers. Conclusions are limited by the high dropout rate in the lithium-treated group.
- 28 August 2020
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 30 (7) , 465-469
A Preliminary Study of the Effects of Treatment with Lithium Versus Quetiapine on Attention of Adolescents with Bipolar Disorder
Objectives: Despite attentional deficits being a prominent feature of bipolar disorder, there are limited data on the effects of common treatments for bipolar disorder on attention. Thus, we sought to compare the effects of lithium versus quetiapine on attention in adolescents with bipolar disorder. Methods: Adolescents ages 10–17 with bipolar disorder, type I, who were experiencing a manic or mixed episode, were recruited from outpatient settings and the inpatient psychiatric units at Cincinnati Children's Hospital Medical Center during their first manic episode. Healthy comparison subjects were recruited from outreach programs in the community. Patients were randomized to lithium or quetiapine, administered in a double-dummy, double-blinded manner for 6 weeks. Attentional deficits were assessed in all groups using the Identical Pairs Continuous Performance Task at baseline and at week 6. Results: Patients with bipolar disorder ( n = 79) had impaired attention relative to the healthy group ( n = 57) at both baseline and after 6 weeks of treatment. The lithium-treated group ( n = 30) had poorer attentional performance than the healthy group at week 6. There was a difference in change in performance between lithium- and quetiapine-treated ( n = 49) groups. Conclusion: Youth with bipolar disorder may have impaired attention relative to their healthy peers. Conclusions are limited by the high dropout rate in the lithium-treated group.
- 1 September 2014
- Published by Elsevier in Psychiatry Research
- Vol. 223 (3) , 268-270
The effects of carbamazepine on prefrontal activation in manic youth with bipolar disorder
- 1 September 2014
- Published by Elsevier in Psychiatry Research
- Vol. 223 (3) , 268-270
The effects of carbamazepine on prefrontal activation in manic youth with bipolar disorder
Neurofunctional changes in adolescent cannabis users with and without bipolar disorder
Aims: To compare regional brain activation among adolescents with bipolar disorder and co‐occurring cannabis use disorder.Design: Cross‐sectional study.Setting: Cincinnati, OH, USA.Participants: Adolescents with bipolar disorder (BP, n = 14), adolescents with cannabis use disorder (MJ, n = 13), adolescents with co‐occurring cannabis use and bipolar disorders (BPMJ, n = 25) and healthy adolescents (HC, n = 15).Measurements: Cannabis craving, substance use, Blood Oxygenation Level Dependent (BOLD) signal assessed by the Marijuana Craving Questionnaire (MCQ), Teen‐Addiction Severity Index (T‐ASI) and a cannabis cue–reactivity task during a functional magnetic resonance imaging (fMRI) session, respectively.Findings: The BP group exhibited significantly greater brain activation than the BPMJ group in the right amygdala (F = 4.14, P = 0.046), left nucleus accumbens (F = 3.8, P = 0.02), left thalamus (F = 3.8, P < 0.05) and the right thalamus (F = 6.2, P = 0.02). The BP group exhibited significantly greater activation than the HC group in the left nucleus accumbens (F = 11.5, P = 0.0001), right thalamus (F = 4.9, P = 0.03) and the left striatum (F = 3.6, P = 0.04). Left amygdala activation of the BPMJ group trended towards being significantly negatively correlated with the number of joints smoked (R = −0.4, P = 0.06).Conclusions: Bipolar adolescents with comorbid cannabis use do not exhibit the same over‐activation of the regions involved in emotional processing as seen in adolescents with bipolar disorder alone. The absence of these findings in patients with comorbid bipolar and cannabis use disorders suggests that these individuals may have a unique endophenotype of bipolar disorder or that cannabis use may alter brain activation uniquely in bipolar disorder patients who use cannabis.
Neurofunctional changes in adolescent cannabis users with and without bipolar disorder
Aims: To compare regional brain activation among adolescents with bipolar disorder and co‐occurring cannabis use disorder.Design: Cross‐sectional study.Setting: Cincinnati, OH, USA.Participants: Adolescents with bipolar disorder (BP, n = 14), adolescents with cannabis use disorder (MJ, n = 13), adolescents with co‐occurring cannabis use and bipolar disorders (BPMJ, n = 25) and healthy adolescents (HC, n = 15).Measurements: Cannabis craving, substance use, Blood Oxygenation Level Dependent (BOLD) signal assessed by the Marijuana Craving Questionnaire (MCQ), Teen‐Addiction Severity Index (T‐ASI) and a cannabis cue–reactivity task during a functional magnetic resonance imaging (fMRI) session, respectively.Findings: The BP group exhibited significantly greater brain activation than the BPMJ group in the right amygdala (F = 4.14, P = 0.046), left nucleus accumbens (F = 3.8, P = 0.02), left thalamus (F = 3.8, P < 0.05) and the right thalamus (F = 6.2, P = 0.02). The BP group exhibited significantly greater activation than the HC group in the left nucleus accumbens (F = 11.5, P = 0.0001), right thalamus (F = 4.9, P = 0.03) and the left striatum (F = 3.6, P = 0.04). Left amygdala activation of the BPMJ group trended towards being significantly negatively correlated with the number of joints smoked (R = −0.4, P = 0.06).Conclusions: Bipolar adolescents with comorbid cannabis use do not exhibit the same over‐activation of the regions involved in emotional processing as seen in adolescents with bipolar disorder alone. The absence of these findings in patients with comorbid bipolar and cannabis use disorders suggests that these individuals may have a unique endophenotype of bipolar disorder or that cannabis use may alter brain activation uniquely in bipolar disorder patients who use cannabis.
- 1 July 2014
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 53 (7) , 771-779
Risk and Protective Factors Associated With Substance Use Disorders in Adolescents With First-Episode Mania
- 1 July 2014
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 53 (7) , 771-779
Risk and Protective Factors Associated With Substance Use Disorders in Adolescents With First-Episode Mania
- 1 January 2014
- Published by Taylor & Francis in Journal of Dual Diagnosis
- Vol. 10 (1) , 39-43
N-acetyl Aspartate Levels in Adolescents With Bipolar and/or Cannabis Use Disorders
Objective: Bipolar and cannabis use disorders commonly co-occur during adolescence, and neurochemical studies may help clarify the pathophysiology underlying this co-occurrence. This study compared metabolite concentrations in the left ventral lateral prefrontal cortex among adolescents with bipolar disorder (bipolar group; n = 14), adolescents with a cannabis use disorder (cannabis use group; n = 13), adolescents with cannabis use and bipolar disorders (bipolar and cannabis group; n = 25), and healthy adolescents (healthy controls; n = 15). We hypothesized that adolescents with bipolar disorder (with or without cannabis use disorder) would have decreased N-acetyl aspartate levels in the ventral lateral prefrontal cortex compared to the other groups and that the bipolar and cannabis group would have the lowest N-acetyl aspartate levels of all groups. Methods: N-acetyl aspartate concentrations in the left ventral lateral prefrontal cortex were obtained using proton magnetic resonance spectroscopy. Results: Adolescents with bipolar disorder showed significantly lower left ventral lateral prefrontal cortex N-acetyl aspartate levels, but post hoc analyses indicated that this was primarily due to increased N-acetyl aspartate levels in the cannabis group. The cannabis use disorder group had significantly higher N-acetyl aspartate levels compared to the bipolar disorder and the bipolar and cannabis groups (p = .0002 and p = .0002, respectively). Pearson correlations revealed a significant positive correlation between amount of cannabis used and N-acetyl aspartate concentrations. Conclusions: Adolescents with cannabis use disorder showed higher levels of N-acetyl aspartate concentrations that were significantly positively associated with the amount of cannabis used; however, this finding was not present in adolescents with comorbid bipolar disorder.
- 1 January 2014
- Published by Taylor & Francis in Journal of Dual Diagnosis
- Vol. 10 (1) , 39-43
N-acetyl Aspartate Levels in Adolescents With Bipolar and/or Cannabis Use Disorders
Objective: Bipolar and cannabis use disorders commonly co-occur during adolescence, and neurochemical studies may help clarify the pathophysiology underlying this co-occurrence. This study compared metabolite concentrations in the left ventral lateral prefrontal cortex among adolescents with bipolar disorder (bipolar group; n = 14), adolescents with a cannabis use disorder (cannabis use group; n = 13), adolescents with cannabis use and bipolar disorders (bipolar and cannabis group; n = 25), and healthy adolescents (healthy controls; n = 15). We hypothesized that adolescents with bipolar disorder (with or without cannabis use disorder) would have decreased N-acetyl aspartate levels in the ventral lateral prefrontal cortex compared to the other groups and that the bipolar and cannabis group would have the lowest N-acetyl aspartate levels of all groups. Methods: N-acetyl aspartate concentrations in the left ventral lateral prefrontal cortex were obtained using proton magnetic resonance spectroscopy. Results: Adolescents with bipolar disorder showed significantly lower left ventral lateral prefrontal cortex N-acetyl aspartate levels, but post hoc analyses indicated that this was primarily due to increased N-acetyl aspartate levels in the cannabis group. The cannabis use disorder group had significantly higher N-acetyl aspartate levels compared to the bipolar disorder and the bipolar and cannabis groups (p = .0002 and p = .0002, respectively). Pearson correlations revealed a significant positive correlation between amount of cannabis used and N-acetyl aspartate concentrations. Conclusions: Adolescents with cannabis use disorder showed higher levels of N-acetyl aspartate concentrations that were significantly positively associated with the amount of cannabis used; however, this finding was not present in adolescents with comorbid bipolar disorder.
- 25 February 2013
- Published by Wiley in Bipolar Disorders
- Vol. 15 (2) , 150-152
Treatment of youth with bipolar disorder: long‐term versus maintenance
- 25 February 2013
- Published by Wiley in Bipolar Disorders
- Vol. 15 (2) , 150-152
Treatment of youth with bipolar disorder: long‐term versus maintenance
- Open Access
- 18 April 2012
- Published by Elsevier in Comprehensive Psychiatry
- Vol. 53 (7) , 1000-1005
Health-related quality of life as measured by the child health questionnaire in adolescents with bipolar disorder treated with olanzapine
- 18 April 2012
- Published by Elsevier in Comprehensive Psychiatry
- Vol. 53 (7) , 1000-1005
Open AccessHealth-related quality of life as measured by the child health questionnaire in adolescents with bipolar disorder treated with olanzapine
- 1 January 2012
- Vol. 49 (2) , 112-20
The effects of ziprasidone on prefrontal and amygdalar activation in manic youth with bipolar disorder.
Prior research has found that manic adolescents with bipolar disorder exhibit neurofunctional changes in the amygdala and prefrontal cortex following treatment with some pharmacological agents. We examined the neurofunctional effects of ziprasidone in manic adolescents. Manic adolescents with bipolar disorder (n=23) participated in a placebo-controlled study of ziprasidone and underwent a functional magnetic resonance imaging scanning session while performing a task of sustained attention at baseline, prior to treatment as well as on days 7 and 28 (or early termination) of treatment. A comparison group of healthy adolescents (n=10) participated in a single scanning session. Region of interest analyses were performed to assess activation changes associated with treatment in Brodmann Areas (BA) 10, 11 and 47 and in the amygdala. Compared with placebo, treatment with ziprasidone was associated with greater increases over time in right BA 11 and 47 activation. These effects were not associated with differences in symptom improvement between the treatment groups. Patients who subsequently responded to ziprasidone showed significantly greater deactivation in the right Brodmann area 47 at baseline than those who did not respond to ziprasidone. Similarly, among the bipolar adolescents who were treated with ziprasidone, baseline activation in right BA 47 was negatively correlated with improvement in Young Mania Rating Scale (YMRS) score. The small sample size limits the ability to detect significant group differences in other regions of interest. Healthy comparison subjects were scanned only at a single timepoint, which limits the interpretation of the results. Ziprasidone is not currently approved by the United States Food and Drug Administration for the treatment of adolescents with mania, and, therefore, the clinical relevance of these results is limited. The increases in right BA 11 and 47 activation observed during sustained attention tasks following ziprasidone treatment and the association identified between lower baseline BA 47 activation and ziprasidone treatment response suggests that ziprasidone may correct prefrontal dysfunction in manic adolescents with bipolar disorder.
- 1 January 2012
- Vol. 49 (2) , 112-20
The effects of ziprasidone on prefrontal and amygdalar activation in manic youth with bipolar disorder.
Prior research has found that manic adolescents with bipolar disorder exhibit neurofunctional changes in the amygdala and prefrontal cortex following treatment with some pharmacological agents. We examined the neurofunctional effects of ziprasidone in manic adolescents. Manic adolescents with bipolar disorder (n=23) participated in a placebo-controlled study of ziprasidone and underwent a functional magnetic resonance imaging scanning session while performing a task of sustained attention at baseline, prior to treatment as well as on days 7 and 28 (or early termination) of treatment. A comparison group of healthy adolescents (n=10) participated in a single scanning session. Region of interest analyses were performed to assess activation changes associated with treatment in Brodmann Areas (BA) 10, 11 and 47 and in the amygdala. Compared with placebo, treatment with ziprasidone was associated with greater increases over time in right BA 11 and 47 activation. These effects were not associated with differences in symptom improvement between the treatment groups. Patients who subsequently responded to ziprasidone showed significantly greater deactivation in the right Brodmann area 47 at baseline than those who did not respond to ziprasidone. Similarly, among the bipolar adolescents who were treated with ziprasidone, baseline activation in right BA 47 was negatively correlated with improvement in Young Mania Rating Scale (YMRS) score. The small sample size limits the ability to detect significant group differences in other regions of interest. Healthy comparison subjects were scanned only at a single timepoint, which limits the interpretation of the results. Ziprasidone is not currently approved by the United States Food and Drug Administration for the treatment of adolescents with mania, and, therefore, the clinical relevance of these results is limited. The increases in right BA 11 and 47 activation observed during sustained attention tasks following ziprasidone treatment and the association identified between lower baseline BA 47 activation and ziprasidone treatment response suggests that ziprasidone may correct prefrontal dysfunction in manic adolescents with bipolar disorder.
- 1 January 2012
- Published by Taylor & Francis in Journal of Dual Diagnosis
- Vol. 8 (1) , 13-18
Diagnosing Alcohol and Cannabis Use Disorders in Adolescents With Bipolar Disorder: A Preliminary Investigation
The aim of this report was to examine the accuracy of diagnosing substance use disorders in manic adolescents with bipolar disorder. The substance use disorder modules of the KSADS-PL were administered to a sample of 80 manic adolescents (12-21 years old) with co-occurring bipolar and substance use disorders. Initial substance use disorder diagnoses obtained from the KSADS-PL were then compared to a best-estimate diagnosis derived from all available information, including a second diagnostic interview, the Child Semi-Structured Assessment for the Genetics of Alcoholism, Adolescent version (C-SSAGA-A). Relatively low diagnostic agreement was achieved across the initial and the best estimate diagnoses for both alcohol and cannabis use disorders. Age, race, and sex did not predict diagnostic agreement between the two evaluations. Results of this study call for more research on diagnosing substance use disorders and suggest that a single interview alone may not be accurate for diagnosing substance use disorders in manic adolescents with bipolar disorder.
- 1 January 2012
- Published by Taylor & Francis in Journal of Dual Diagnosis
- Vol. 8 (1) , 13-18
Diagnosing Alcohol and Cannabis Use Disorders in Adolescents With Bipolar Disorder: A Preliminary Investigation
The aim of this report was to examine the accuracy of diagnosing substance use disorders in manic adolescents with bipolar disorder. The substance use disorder modules of the KSADS-PL were administered to a sample of 80 manic adolescents (12-21 years old) with co-occurring bipolar and substance use disorders. Initial substance use disorder diagnoses obtained from the KSADS-PL were then compared to a best-estimate diagnosis derived from all available information, including a second diagnostic interview, the Child Semi-Structured Assessment for the Genetics of Alcoholism, Adolescent version (C-SSAGA-A). Relatively low diagnostic agreement was achieved across the initial and the best estimate diagnoses for both alcohol and cannabis use disorders. Age, race, and sex did not predict diagnostic agreement between the two evaluations. Results of this study call for more research on diagnosing substance use disorders and suggest that a single interview alone may not be accurate for diagnosing substance use disorders in manic adolescents with bipolar disorder.
- 1 October 2011
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 50 (10) , 1017-1026
Progression of Amygdala Volumetric Abnormalities in Adolescents After Their First Manic Episode
- 1 October 2011
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 50 (10) , 1017-1026
Progression of Amygdala Volumetric Abnormalities in Adolescents After Their First Manic Episode